ImmunOs Therapeutics AG, a Swiss biotech developing candidate therapies for cancer, has raised $11 million in a Series C financing round to advance its lead clinical programme targeting solid tumours. The product, IOS-1002, is a human leukocyte antigen (HLA)-based protein that block receptors in the innate immune system. The financing follows a Series B round that raised $74 million in 2022.
The latest financing was led by the existing investors Gimv, Pfizer Ventures, Mission BioCapital and BioMed Partners and supported by the new investor Double Point Ventures.